A German Biotech Just Raised Millions to Target Heart Disease Differently

Jan de Vries · 2026-08-28

There's a fresh player in the European biotech scene, and it's coming out of the gate with a significant vote of confidence. Revier Therapeutics, a new company based in Heidelberg, Germany, has officially launched with a $6.5 million Seed round. This isn't just another startup story—it's a focused effort to tackle some of the most persistent challenges in cardiovascular medicine. The funding was led by KHAN Technology Transfer Fund II. They were joined by High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors organized through Revier Invest Heidelberg. That coalition of backers suggests they see something special here. ### The Unmet Need in Cardiometabolic Disease So, what's the big deal? The company's mission centers on cardiometabolic diseases—conditions like heart failure and atherosclerosis that affect millions. Despite decades of research, many patients still hit a wall. Treatment options can be limited, often managing symptoms rather than addressing the root cause of the disease. Prof. Eva van Rooij, the company's co-founder and CEO, put it plainly. She said that for patients with specific types of heart failure and cardiovascular disease, targeted treatments are still scarce. The next wave of medicine, she argues, has to go deeper. It needs to fix the faulty biology driving the illness to create real, long-term solutions. ### A More Precise Therapeutic Approach Here's where Revier's strategy gets interesting. They're going after a specific family of enzymes called class IIa histone deacetylases, or HDACs. Think of earlier HDAC inhibitors as a blunt instrument—they affected multiple enzyme classes, which often led to nasty side effects that limited how much medicine a patient could tolerate. Revier is designing what they call 'first-in-class' small molecules. These are pills intended to be highly selective. The goal is to inhibit only the disease-causing activity of these enzymes while leaving their essential, healthy functions completely alone. Prof. Johannes Backs, the company's scientific founder, explained that this precision is key to being both effective and safe. - **Target:** Class IIa HDAC enzymes specifically. - **Method:** Orally available pills (small molecules). - **Goal:** Inhibit bad activity, preserve good function, avoid the pitfalls of older drugs. ### What the Investors Are Saying Michael Hamacher from KHAN Technology Transfer Fund II didn't hold back on his optimism. He called Revier's approach a 'differentiated strategy' with the potential to finally unlock the therapeutic promise scientists have seen in HDAC biology for years. He pointed to the combination of a standout leadership team and deep scientific expertise as the reason this company could actually reshape patient care. The money has a clear job. It will fuel the development of Revier's preclinical pipeline, focusing first on two major indications: 1. Heart failure with preserved ejection fraction (HFpEF) 2. Atherosclerotic cardiovascular disease (ASCVD) Beyond the lab work, the funding will also help build out the company's operational and clinical teams. It's the foundational capital needed to transition from a promising idea to a clinical-stage reality. For professionals watching the European startup ecosystem, especially in life sciences, this launch is a signal. It shows continued investor appetite for deep-tech, science-driven ventures that aim to solve hard problems with novel biology. The road from here to the clinic is long, but Revier Therapeutics is now firmly on it.